Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023

March 23, 2023

IMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023

March 22, 2023

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

March 21, 2023

Financial Events

Fourth Quarter 2022 Financial Results

March 30, 2023 at 11:00 AM EDT

Imunon, Inc. Third Quarter 2022 Earnings Call

November 14, 2022 at 11:00 AM EST